Topically applied antithrombotic agents offer a new therapeutic approach to the prevention of microvascular thrombosis.
In the quest to develop optimal antithrombotic therapies for reconstructive microsurgery, with concomitant minimization of patient risk for generalized hemorrhage, surgeons have been turning to localized intraarterial delivery of various agents. An extension of this direction is to design agents that bind specifically to the site of thrombogenesis and effectively inhibit or prevent the buildup of thrombotic components. Progress in this direction must make use of the latest developments in the molecular understanding of coagulation, platelet adhesion/aggregation, and fibrinolytic processes. This article reviews pertinent developments in the biochemical understanding of thrombosis and discusses current avenues of investigation in the development of topically applied agents that help prevent microvascular thrombotic occlusion.
Cooley
B C
BC
Department of Orthopaedic Surgery, Medical College of Wisconsin, Milwaukee 53226.
Gould
J S
JS
D000287:Administration, Topical; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008833:Microcirculation / Q000502:physiology; D013927:Thrombosis / Q000503:physiopathology / Q000517:prevention & control*
D005343:Fibrinolytic Agents